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Abstract
Background: Rheumatic heart disease (RHD), the long-term consequence of rheumatic fever, accounts for most
cardiovascular morbidity and mortality among young adults in developing countries. However, data on contemporary
outcomes from resource constrained areas are limited.
Methods: A prospective cohort study of participants aged 5–60 years with established RHD was conducted in Kampala,
Uganda, in which clinical exam, echocardiography, electrocardiography (ECG), and laboratory evaluation were done
every 3 months and every 4-week benzathine penicillin prophylaxis was prescribed. Participants were followed up for
12 months and outcomes and predictors of morbidity and mortality were assessed using Kaplan Meier curves and Cox
proportional hazards models.
Results: Of 449 subjects, 66.8% (300/449) were females, median age was 30 (interquartile range 20). 73.7% (331/449) had
atleast one follow up visit. Among these, 35% (116/331) developed decompensated heart failure and, 63.7% (211/331)
developed atrial fibrillation. Heart failure was associated with poor penicillin adherence (OR = 3.3, CI 2–5.4, p = 0.001), and
left ventricular end diastolic diameter greater than 55 mm (OR = 3.16, CI 1.73–5.76, p = 0.001). Atrial fibrillation was
associated with left atrial diameter >40 mm (OR = 7.5, CI 2.4–9.8, p = 0.001).
There were 59 deaths with a 1-year mortality rate of 17.8%. Most deaths occurred within the first three months of
presentation. Subjects whose average adherence to benzathine penicillin was <80% had significantly greater mortality
(31% vs. 9%, log rank p < 0.001). In multivariate analysis, the risk of death among those with poor penicillin adherence
was 3.81 times higher than those with better adherence (HR = 3.81, CI 1.92–7.63, p = 0.001). Other predictors of 1 year
mortality included heart failure (HR 8.36, CI 3.28–21.31, p = 0.001) and left ventricular end diastolic diameter greater than
55 mm (HR = 1.93, CI 1.07–3.49, p = 0.02).
Conclusion: In this study of RHD in Uganda, morbidity and mortality within 1 year of presentation were higher than in
recently published from other low and middle income countries. Suboptimal adherence to benzathine penicillin injections
was associated with incident heart failure and mortality over 1 year. Future studies should test interventions to improve
adherence among patients with advanced disease who are at the highest risk of mortality.
Keywords: Rheumatic heart disease, Predictors, Morbidity, Mortality, Outcomes, Uganda
* Correspondence: emmkol@hotmail.com
1Uganda Heart Institute, Kampala, Uganda
2Department of Medicine, School of Medicine Makerere University, Kampala,
Uganda
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Okello et al. BMC Cardiovascular Disorders  (2017) 17:20 
DOI 10.1186/s12872-016-0451-8
Background
Rheumatic heart disease (RHD) remains a leading cause
of morbidity and mortality among young adults in the
developing world, accounting for at least 345,000 deaths
annually [1, 2].
RHD is the long term consequence of rheumatic fever,
an autoimmune response to Group A streptococcal pha-
ryngitis [3].
Without prophylaxis, patients with RHD are at risk of
recurrent attacks of rheumatic fever resulting in ongoing
inflammation and fibrosis with consequent valvular
damage [4, 5].
In Uganda, RHD is the most common cause of heart
disease in young adults [6]. As is true in many under-
served areas, Ugandan patients tend to present late in
the disease course, and almost half present with a com-
plication [7].
Longitudinal studies of acute rheumatic fever (ARF)
and RHD suggest that adherence to penicillin prophy-
laxis can significantly decrease disease progression and
mortality [5, 8, 9].
However, these data come from patients early in dis-
ease course, who were most often enrolled following
diagnosis of ARF. Unfortunately, our patients tend to
present much later with complicated RHD. Whether
penicillin prophylaxis improves outcomes among pa-
tients with more advanced disease is less clear.
Additionally, the lack of good quality data on RHD
progression and outcomes in these regions limits efforts
to target appropriate disease prevention and treatment
strategies in settings where cardiac surgery is not widely
available. We therefore aimed to describe the incidence
of morbidity and mortality among a cohort of Ugandan
patients with RHD within the first year after diagnosis,
and to determine predictors of these events.
Methods
A prospective cohort study of patients with established
RHD was conducted in Kampala, Uganda from 2011 to
2013. The study was conducted in parallel with re-
cruitment into a global RHD registry (the REMEDY
study) [10].
Subjects were co enrolled and underwent additional
investigations as part of this study. Participants aged
5–60 years were enrolled at initial presentation and
followed up quarterly for 12 months. Recruitment oc-
curred from within the Mulago National Referral
hospital including; the Uganda Heart Institute, the in-
patient cardiology ward, and the outpatient cardiac
clinics. Additionally, physicians from other Ugandan
hospitals were invited to refer patients to the study site.
Participants were eligible for the study if they met
World Heart Federation criteria for definite RHD by
echocardiography. Participants who were unable to
consent or who had morphological features of congenital
or degenerative valve disease were excluded.
Study procedures
At baseline, a detailed history was taken from consenting
participants, after which they underwent physical examin-
ation, chest x-ray, 12-lead electrocardiogram, and venous
blood draw for analysis of antistreptolysin O titers and C
reactive protein. At each subsequent visit, interval history
and exam were obtained, including symptoms of ARF,
ECG, chest x-ray, and laboratory tests were repeated. All
patients were prescribed 4 weekly intramuscular ben-
zathine penicillin prophylaxis. RHD complications were
treated according to local standards of care. Penicillin in-
jections were recorded on a patient adherence card and
the percentage adherence was determined each quarter by
dividing the number of injections received by the number
prescribed. Cumulative adherence was then averaged for
each quarter over the 12 months. Adherence to >80% of
prescribed injections is considered optimal.
Echocardiography
A standardized echocardiogram was performed according
to American Society of Echocardiography guidelines [11, 12]
using a GE Vivid 7 (GE, USA). Two-dimensional and color
images as well as M-mode were used to obtain left ventricu-
lar end diastolic diameter (LVDD), left ventricular end sys-
tolic diameter (LVSD), and ejection fraction (EF).
Mitral stenosis was determined by pressure half-time,
mean gradient, continuity equation and/or planimetry of
the valve orifice in the parasternal short axis view. Mitral
stenosis was graded according to mitral valve area (MVA)
as mild (1.6–2.0 cm2), moderate (1.1–1.5 cm2), or severe
(<1 cm2). Mitral regurgitation was graded according to
regurgitant jet area as mild (<4 cm2), moderate (4–8 cm2),
or severe (>8 cm2). In addition, severe MR was diagnosed
if there was flow reversal in the pulmonary veins. Aortic
stenosis was determined by the calculated valve area by
continuity equation and graded as mild (aortic valve area
1.6–2 cm2), moderate (1.1–1.5 cm2), or severe (<1 cm2).
Aortic regurgitation was determined by pressure half time
and graded as mild (PHT >500 ms), moderate (PHT =
250–500 ms) or severe (PHT <250 ms). Tricuspid and
pulmonary valve involvement were rare and were not
quantified for this study.
Biomarkers
Six mililiters of venous blood was drawn at each visit to
measure antistreptolysin O titer (ASO) and C reactive
protein (CRP). ASO titers were estimated using the latex
agglutination technique of immunoturbidimitry. (Cobas
Integra 400, Roche, Germany). A conservative test value
of 240 Todd units was taken as positive to cater for the
variation in ASO titers for the different age ranges [13].
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CRP was determined using the particle enhanced turbi-
dimitry assay. (Cobas Integra 400, Roche, Germany).
Outcomes measures
Outcome measures, assessed at each visit, included car-
diac related death (determined based on death certifi-
cates), atrial fibrillation (Minnesota coding, [14] heart
failure (Framingham [15]) and severity (NYHA classifi-
cation), Stroke (clinical neurological deficit and confirm-
ation with head CT), recurrent ARF (2006 NIH/WHO
criteria) [16], and infective endocarditis (clinical presen-
tation, blood cultures and echocardiography) [17].
Statistical analysis
Using the formula proposed by Kelsey [18], we esti-
mated, based on prior studies [19, 20], that 50% of the
study cohort would achieve 80% adherence to every
4 week injections of benzathine Penicillin. We also ex-
pected a rate of recurrence of complications of 5% in
those achieving less than 80% adherence from previous
studies. Therefore, with a two sided alpha and 80%
power, a sample size of 440 (220 per group including
10% allowance for losses to follow up), our study would
detect atleast 8% difference in complication rate between
participants with >80% adherence versus those with
<80% adherence.
Univariate and bivariate analyses were conducted
using frequencies and chi square tests for categorical
variables, and means (standard deviation)/median (IQR)
and Students t- test/ANOVA for continuous variables.
Time to occurrence of morbidity or mortality outcomes
were described using Kaplan-Meier curves. Differences
between curves were described using log rank tests and
hazard ratios (95% confidence intervals) were estimated
using multivariate Cox proportional hazards models re-
spectively. Covariates with p < 0.2 in the univariate (un-
adjusted) analysis or those with biological plausibility for
outcomes were added into a multivariable model. Model
goodness of fit was assessed using likelihood ratio tests
(LRTs). We repeated all analyses separately by gender
given the expected female predominance of RHD seen
in our cohort. All data were managed using EPI data for-
mat 3.0 (Odensk, Denmark) [21] and were analyzed
using STATA 12 (STATA Corporation, College Station,
Texas, USA). A p-value <0.05 was considered statisti-
cally significant.
Results
Baseline characteristics of the 449 study participation can
be found in Table 1. There were twice as many female as
male participants (300 female vs. 149 males). The mean
age of enrollment was 31.4 years. As previously reported
[7], initial presentation of RHD in our cohort occurred
late in disease. At the time of presentation, 46% had heart
Table 1 Baseline characteristics of study participants
Variable Category N (%)
















Small business 119 (26.5)
Civil servant 9 (2.0)
NYHA Class
Class 1 228 (50.8)
Class 2 91 (20.3)
Class 3 110 (24.5)
Class 4 20 (0.9)
Complications
Heart failure 208 (46.3)
ARF 61 (13.6)
Stroke 9 (2.0)
Infect Endocarditis 18 (4.0)
Atrial fibrillation 91 (20.3)
Echocardiography
LVIDd >55 mm 211 (46.9)
LVIDs >40 mm 146 (32.5)
Left atrial diameter >40 mm 364 (81.1)
Ejection fraction <40 28 (6.2)
Mitral regurgitation 304 (67.7)
Mitral stenosis 131 (29.1)
Aortic regurgitation 150 (33.4)
Aortic stenosis 17 (3.8)
Laboratory
ASO titer >240 61 (13.6)
C reactive protein >5 152(33.9)
N number, NYHA New York Heart Association, ARF acute rheumatic fever,
LVIDd left ventricular internal dimension in diastole, LVIDs left ventricular
internal dimension in systole, ASO anti-streptolysin-O
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failure of any stage, out of which 29% of patients were
classified as NYHA stage 3 or higher. 9% had had a previ-
ous stroke, 4% had infective endocarditis, and 20% had
atrial fibrillation. One hundred eighteen cases (26.3%)
were lost to follow up and only seen on initial visit. Thus,
outcomes data is determined from the remaining 331
patients.
Morbidity
Complications within 1-year of presentation were fre-
quent and are presented in Fig. 1. Complications were
most likely to occur within the first 3 months of presen-
tation. By the end of the year, an additional 35% (116 pa-
tients) had developed heart failure, 6% (21 patients) had
suffered an attack of recurrent acute rheumatic fever,
64% (211 patients) developed atrial fibrillation, 2% (six
patients) developed infective endocarditis, and 2% (five
patients) developed a stroke. New occurrence of heart
failure was associated with penicillin adherence <80%
(unadjusted OR = 3.3, CI 2.0–5.4, p = 0.001) and left ven-
tricular end diastolic diameter greater than 55 mm (un-
adjusted OR 3.16, 95% CI 1.73–5.76, p = 0.001). Acute
rheumatic fever was associated with younger age
(<15 years, unadjusted OR = 0.92, 95% CI 0.88–0.95, p =
0.001) and poor penicillin adherence (unadjusted OR =
33.9 CI 7.58–151.3, p = 0.001).
Mortality
There were 59 cardiac related deaths in this cohort with
a 1-year mortality of 17.8%. The mean age of death was
29.4 years (+/− 15.5). Most deaths occurred within the
first 3 months of presentation and males had higher risk
of mortality compared to females (Fig. 2).
A univariate analysis of risk factors for mortality is
found in Table 2. Patients were at higher risk of mortal-
ity if they were male (p = 0.001), had heart failure at
presentation (p = 0.001), or had surrogate markers for
heart failure, including left ventricular end diastolic di-
mension greater than 55 mm (p = 0.01), left ventricular
peak systolic dimension greater than 40 mm (p = 0.01),
ejection fraction <40% (p = 0.01). Markers of recent
streptococcal infection or persistent inflammation in-
cluding elevated ASO titer (p = 0.01) or elevated CRP
(p = 0.001) during follow-up were also predictive of
mortality. While severity of mitral stenosis, aortic sten-
osis, and aortic regurgitation were not predictive of
death, severe mitral regurgitation was a risk factor for
1-year mortality (p = 0.001). Additionally, occurrence of
infective endocarditis (0.001) or atrial fibrillation
(0.007) during the study period also increased the risk
of mortality.
Adherence to benzathine penicillin
All patients in this cohort were prescribed every-4-week
injections of benzathine penicillin for streptococcal
prophylaxis. The overall use of penicillin was 67.2%, with
57.5% of patients receiving at least 80% of their injec-
tions. Subjects who averaged less than 80% adherence
had a significantly greater 1-year mortality compared to
those who averaged greater than 80% adherence (31% vs.
9% mortality- for <80% adherence vs >80%adherence in
the overall cohort, log-rank p < 0.001 for both men and
women; Fig. 3).
Fig. 1 Morbidity During the First Year Following Initial RHD Presentation
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Demographic information comparing those who were
adherent to those who were not, separately by gender, is
found in Table 3. Adherence to penicillin decreased with
increasing age (71% of those <15 years compared to 22%
of those >50 years, p < 0.001). Additional factors associ-
ated with poor compliance included no formal education
(p = 0.001), and presence of stroke (0.04) or atrial fibrilla-
tion (p < 0.001). Elevated ASO titers and acute rheumatic
fever at entry into the study showed borderline signifi-
cance for poor penicillin compliance (p = 0.05 and; p =
0.06, respectively). Interestingly, there was no difference in
adherence based on gender (p = 0.093), heart failure at
presentation (p = 0.31), or any of the surrogate markers of
heart failure (Table 3).
Multivariate analysis
In an effort to control for confounding variables, a multi-
variate analysis was conducted. At the univariate level
(Table 2), male sex, heart failure at study entry, severe mi-
tral regurgitation, left ventricular end diastolic dimension
>55 mm, left ventricular end systolic dimension >40 mm,
atrial fibrillation, infective endocarditis, elevated CRP, and
benzathine penicillin adherence less than 80%, were signifi-
cantly associated with increased mortality. After adjustment
in the Cox proportional model, penicillin adherence <80%
(HR = 3.81, 95% CI 1.92–7.63, p = 0.001), heart failure (HR
= 8.36, CI 3.28–21.31, p = 0.001) and left ventricular dia-
stolic diameter > 55 mm (HR= 1.93, CI 1.07–3.49, p = 0.02)
were the only predictors of mortality (Table 4). Left ven-
tricular diastolic diameter >55 mm and heart failure were
not collinear in our model.
Discussion
Results of this first follow up study on outcomes of RHD
in Uganda show a remarkably high mortality within 1-year
of initial diagnosis of RHD, indicating that patients present
for care at a very late stage of disease. The most important
finding of our study is that even when mortality is driven
by progressive heart failure, achieving greater than 80%
adherence to penicillin significantly decreases mortality.
To our knowledge, this is the first study to convincingly
show a mortality benefit of optimal penicillin adherence in
this population of patients with advanced disease who
generally do not have access to cardiac surgery.
In this population, patients with less than 80% penicillin
adherence to monthly injections of benzathine penicillin
were much more likely to die than those who achieved
more than 80% adherence, and this was true for both men
and women. Other predictors of mortality included any
degree of heart failure at baseline, dilated left ventricle,
low ejection fraction, and advanced NYHA functional
class. Our findings extend the results of the larger Global
Registry of Rheumatic Heart Disease (REMEDY) study of
over 3000 patients with RHD from low and middle in-
come countries [10], of which our cohort was a subset.
Mortality in the first year of REMEDY was 11%, somewhat
lower than the 18% seen in the Ugandan cohort. This is
not suprising considering the available resources for RHD
care in Uganda at the time this cohort was recruited
(2011–2013). In REMEDY, congestive heart failure,
NYHA class, and prescription for penicillin for univariate
predictors of mortality; although the association of penicil-
lin prophylaxis with mortality did not persist in multivari-
able models. Penicillin adherence was not reported.
Consistent with REMEDY, females had lower risk of mor-
tality than males in our cohort.
Our study compliments the recently reported registry
findings from the Northern Territory of Australia [22].
The patients in our study had more advanced disease,
and, therefore, morbidity and mortality was significantly
Fig. 2 Kaplan- Meier curve for mortality within one year of initial presentation with rheumatic heart disease
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higher. Among 1149 patients diagnosed with RHD in
the Australian cohort, age, gender, and indigenous status
did not predict the development of heart failure; the effects
of penicillin adherence or surrogate echocardiographic
measures were not evaluated. This study did not evaluate
the effect of penicillin adherence on mortality.
This study adds to previous findings that advanced
valvular disease is common at first presentation [7, 23].
Table 2 Univariate analysis of predictors of mortality stratified by gender
Female Male
HR (95% CI) P value HR (95% CI) P value
Age (Ref: ≤15 years)
16–30 year 1.47 (0.40–5.33) 0.561 0.53 (0.22–1.26) 0.153
31–49 years 0.96 (0.26–3.63) 0.957 0.57 (0.23–1.41) 0.226
>50 year 2.21 (0.59–8.32) 0.242 0.36 (0.047–2.86) 0.339
Education level (Ref: no education)
Primary 1.26 (0.42–3.73) 0.682 1.60 (0.21–12.04) 0.650
Secondary 0.77 (0.22–2.62) 0.672 1.56 (0.20–12.00) 0.671
Post secondary 0.23 (0.03–2.04) 0.187 0.44 (0.03–7.04) 0.562
Occupation (Ref: unemployed)
Student 0.60 (0.24–1.50) 0.274 1.09 (0.45–2.63) 0.845
Small business 0.41 (0.14–1.14) 0.086 0.32 (0.086–1.23) 0.099
Civil servant 0.21 (0.06–0.75) 0.016 0.504 (0.17–1.45) 0.206
Penicillin adherence (Ref: ≥80%)
<80% adherence 3.82 (1.55–9.38) 0.003 7.34 (2.56–21.11) 0.001
NYHA at baseline (Ref: NYHA 1)
Class 2 0.50 (0.17–1.50) 0.218 0.47 (0.17–1.29) 0.147
Class 3 0.97 (0.38–2.48) 0.947 0.62 (0.25–1.52) 0.305
Class 4 8.56 (2.48–29.52) 0.001 1.42 (0.32–6.18) 0.640
Mitral regurgitation (Ref: Mild MR)
Moderate 2.86 (0.36–22.88) 0.322 0.43 (0.12–1.62) 0.215
Severe 8.38 (1.12–62.43) 0.038 1.47 (0.51–4.305) 0.740
Mitral stenosis (Ref: Mild MS)
Moderate 0.51 (0.13–2.02) 0.334 0.37 (0.09–1.50) 0.165
Severe 0.41 (0.09–1.84) 0.244 0.28 (0.062–1.25) 0.097
Aortic regurgitation (Ref: Mild AR)
Moderate 1.88 (0.60–5.92) 0.282 0.79 (0.25–2.509) 0.697
Severe 1.98 (0.38–10.20) 0.415 0.84 (0.25–2.87) 0.781
LVIDd >55 mm 1.90 (0.57–6.29) 0.290 1.95 (0.87–4.38) 0.105
LVIDs >45 mm 2.02 (0.48–8.49) 0.340 2.02 (0.77–5.28) 0.152
Ejection fraction >40% 0.50 (0.24–1.04) 0.060 0.60 (0.29–1.23) 0.167
Fractional shortening >20% 3.61 (1.09–11.93) 0.035 1.62 (0.49–5.36) 0.420
Pericardial effusion 0.26 (0.10–0.64) 0.004 0.82 (0.25–2.71) 0.750
Heart failure 12.32 (3.73–40.70) 0.001 11.07 (2.62–46.67) 0.001
Atrial fibrillation 1.87 (0.87–4.03) 2.06 (0.98–4.34) 0.056
Infective endocarditis 4.19 (1.45–12.08) 0.008 2.40 (0.73–7.93) 0.150
Acute rheumatic fever 1.09 (0.38–3.13) 0.870 1.42 (0.58–3.48) 0.440
Antistreptolysin O titers >240 1.14 (0.39–3.26) 0.810 1.54 (0.63–3.77) 0.340
C reactive protein >5 mg/L 2.78 (1.31–5.87) 0.007 1.78 (0.87–3.66) 0.110
Bolded results represent p < 0.05. Abbreviations as in Table 1
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In the present study, acutely decompensated heart fail-
ure at baseline predicted mortality, but acute decompen-
sation of heart failure and atrial fibrillation also occurred
as the most common complications over the 12 months.
This was probably due to progression of old lesions as
well as occurrence of new heart failure in those who did
not have signs at enrollment. Atrial fibrillation was ex-
plained by the large majority of participants having left
atrial diameter greater than 40 mm. Interestingly, stroke
rates remained low despite the high prevalence of atrial
fibrillation. This could be explained by the fact most pa-
tients were prescribed Coumadin or an antiplatelet in
those without facilities for monitoring the international
normalized ratio (INR).
In the study by Bland and Jones [4], where 1000 cases of
rheumatic heart disease were followed up for over 20 years,
dilated left ventricle and heart failure at baseline accounted
for over 80% mortality in the first 10 years. Although our
follow up lasted only a year, our study seems to concur
with their observation. Heart failure and dilated left ven-
tricle at baseline were some of the independent predictors
of mortality. Furthermore, the follow up by Bland et al.
started in the pre penicillin era and only the last 5 years of
the study had participants receiving penicillin [4].
More recent studies indicate that the prognosis of
RHD is poor if left untreated—mortality occurs early
with an average age of death of 26 years [20].
Gunther et al. [20] have reported that the annual mor-
tality rate from RHD at a center in Ethiopia was 12.5%,
about the same in our study where the annual mortality
was 17.6%. The average age among participants who
died in our study was 29.4 years, confirming the aggres-
sive nature and poor prognosis of RHD in Uganda.
In the present study, poor adherence to penicillin was a
major risk factor for death, but was also associated with
complications such as atrial fibrillation, acute rheumatic
fever and heart failure. Acute rheumatic fever recurrence
was common and was predictably associated with poor
penicillin adherence. Although younger people tended to
be more adherent to penicillin, they were also more likely
to suffer recurrence of disease. This is likely because chil-
dren and adolescents are more likely to live in crowded
conditions such as schools, a favorable environment for
the spread of Group A streptococcal infection.
Intramuscular benzathine penicillin injection is the
main stay of treatment among patients with chronic
rheumatic heart disease. Penicillin, given either monthly
or every 3 weeks reduces the rate of recurrence of acute
rheumatic fever among patients with a history of rheum-
atic fever [24, 25], With good adherence to penicillin,
the prognosis of RHD has been observed to improve,
with more adherent patients experiencing less episodes
of acute rheumatic fever. Tompkins et al. [5], in a 5 year
follow of children with ARF and RHD showed that there
was no mortality in the group that was fully adherent to
penicillin. A small number of deaths occurred among
patients who were non-adherent to prophylaxis or
who had recurrent attacks of ARF and infective endo-
carditis [5].
Adequate penicillin adherence is generally defined as
adherence level of 80% and above, calculated from the
number of injections in a given period, divided by the
number of injections expected in that period. Due to a
number of factors including fear of painful injection,
lack of access and lack of affordability, patients with
RHD in Uganda have poor adherence to penicillin [19].
Fig. 3 Kaplan Meir curves of participant survival stratified by benzathine penicillin adherence (<80% versus >80%)
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Table 3 Comparison of baseline characteristics of <80% versus ≥80% average adherence to benzathine penicillin
Female Male
<80% ≥80% P-Value <80% ≥80% P-Value
Age
≤15 years 31 (8.49) 85 (18.24) <0.001 24 (17.91) 39 (18.57) <0.001
16–30 year 66 (18.08) 191 (40.99) 52 (38.81) 91 (43.33)
31–49 years 159 (43.56) 167 (35.84) 38 (28.36) 77 (36.67)
>50 year 109 (29.86) 23 (4.94) 20 (14.93) 3 (1.43)
Education level
No education 86 (23.56) 24 (5.15) <0.001 10 (7.46) 7 (3.33) 0.022
Primary 150 (41.10) 200 (42.92) 61 (45.52) 101 (48.10)
Secondary 80 (21.92) 166 (35.62) 54 (40.30) 69 (32.86)
Post secondary 49 (13.42) 76 (16.31) 9 (6.72) 33 (15.71)
NYHA at baseline
Class 1 191 (52.33) 241 (51.72) 0.823 53 (39.55) 81 (38.57) 0.833
Class 2 97 (26.58) 121 (25.97) 38 (28.36) 58 (27.62)
Class 3 70 (19.18) 98 (21.03) 41 (30.60) 64 (30.48)
Class 4 7 (1.92) 6 (1.29) 2 (1.49) 7 (3.33)
Heart failure
No 201 (55.07) 312 (66.95) <0.001 56 (42.11) 120 (57.14) 0.007
Yes 164 (44.93) 154 (33.05) 77 (57.89) 90 (42.86)
ARF at baseline
No 341 (93.42) 386 (82.83) <0.001 117 (87.31) 177 (84.29) 0.437
Yes 24 (6.58) 80 (17.17) 17 (12.69) 33 (15.71)
Stroke
No 349 (95.62) 465 (99.79) <0.001 129 (96.27) 210 (100) 0.009
Yes 16 (4.38) 1 (0.21) 5 (3.73) 0 (0.0)
Infective endocarditis
No 352 (96.44) 455 (97.64) 0.305 121 (90.30) 210 (100) <0.001
Yes 13 (3.56) 11 (2.36) 13 (9.70) 0 (0.0)
Atrial fibrillation
No 242 (66.30) 419 (89.91) <0.001 102 (76.12) 176 (83.81) 0.077
Yes 123 (33.70) 47 (10.09) 32 (23.88) 34 (16.19)
LVIDd
<55 mm 208 (56.99) 282 (60.52) 0.305 56 (41.79) 109 (51.90) 0.067
≥55 mm 157 (43.01) 184 (39.48) 78 (58.21) 101 (48.10)
LVIDs
<40 mm 253 (69.32) 334 (71.67) 0.459 79 (58.96) 152 (72.38) 0.010
≥40 mm 112 (30.68) 132 (28.33 55 (41.04) 58 (27.62)
Ejection fraction
<40% 92 (25.48) 124 (26.61) 0.715 36 (26.87) 53 (25.24) 0.737
≥40% 269 (74.52) 342 (73.39) 98 (73.13) 157 (74.76)
Left atrial diameter
<40 mm 79 (21.64) 124 (26.61) 0.098 11 (8.21) 31 (14.76) 0.070
≥40 mm 286 (78.36) 342 (73.39) 123 (91.79) 179 (85.24)
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In the present study, adherence to penicillin was simi-
larly low at 57.4%. Our study supports existing guide-
lines that recommend the consideration of lifelong
penicillin prophylaxis among those with severe baseline
RHD [26].
To our knowledge, ours is the first observational study
to show a mortality benefit of >80% adherence com-
pared to <80% adherence in a population with a high
prevalence of advanced disease. Recurrent episodes of
rheumatic fever may lead to severe decompensation and
death among patients who have little reserve. This may
be especially true for patients with severe valvular dys-
function who do not have access to cardiac surgery, and
may even be true for older patients who are thought to
be at low risk for rheumatic fever recurrences.
Limitations
This study has several limitations. First, we acknowledge
the relatively high rate of loss- to- follow- up (26%)
which may have introduced bias into our study; however
this is to be expected for studies conducted in very
resource-limited settings and is in line with the REM-
EDY study (75% with 2-year follow-up visit or telephone
interview). Furthermore, we might expect that those lost
to follow-up were more likely to die and were less likely
to be optimally adherent to penicillin, thus our results
may be biased towards lower estimates of mortality and
lower estimated effectiveness of penicillin.
Another important limitation of our study is the in-
ability to completely adjust for confounding in our mul-
tivariable analysis of the effect of penicillin adherence on
mortality. It should be noted that the <80% and >80%
adherence groups had significant differences in baseline
characteristics, including severity of illness. This is to be
expected given that adherence behaviors likely predated
the enrollment into our RHD registry and may have in-
fluenced the baseline severity of disease. Although we
attempted to adjust for these differences in our multivar-
iable analysis, the possibility of residual confounding
persists. Only a randomized trial of penicillin prophy-
laxis in this population could overcome this limitation.
Finally, we determined adherence based on a ben-
zathine penicillin card marked by the attending health
worker whenever an injection was given. A more sure
method would be to determine penicillin levels to deter-
mine adherence. Finally, most events we followed our
patients for, occurred between the three monthly visits
making it impossible to know the precise time of occur-
rence of events. We tried to overcome this by using
interval assumption during survival analysis.
Conclusion
This study suggests that there is high mortality among
RHD patients in Uganda and that poor adherence to
penicillin and heart failure from advanced valvular dis-
ease predict mortality. Future studies should test inter-
ventions to improve adherence among patients with
advanced disease who are at the highest risk of
mortality.
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Values shown are number (%)
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Sex (Male) 1.63 (0.96–2.77) 0.070
Heart failure at baseline 8.36 (3.28–21.31) 0.001
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